Trx-1 administration suppressed GVHD in a murine model by reducing proliferation, migration to the GVHD target organs, interferon (IFN)-γ production, and ROS accumulation of donor T cells, while maintaining GVL effects [17]. This evidence concerns the gene IFNG and graft versus host disease.